These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 28694851)

  • 1. Comparison Between Alprostadil and Iloprost in Intravenous Treatment of Patients With Chronic Peripheral Arterial Disease.
    Tesloianu DN; Morosanu C; Roata EC; Sorodoc L
    Maedica (Bucur); 2016 Sep; 11(3):186-190. PubMed ID: 28694851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study.
    Altstaedt HO; Berzewski B; Breddin HK; Brockhaus W; Bruhn HD; Cachovan M; Diehm C; Dörrler J; Franke CS; Gruss JD
    Prostaglandins Leukot Essent Fatty Acids; 1993 Aug; 49(2):573-8. PubMed ID: 7692455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between iloprost and alprostadil for protection against ischemia/reperfusion injury in a rat model.
    Çevirme D; Adademir T; Kafalı Başaran E; Şavluk ÖF; Elibol A; Erkanlı Şentürk G; Akkaya H; Yılmaz B
    Turk J Med Sci; 2018 Jun; 48(3):661-669. PubMed ID: 29916227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of iloprost and alprostadil on ischemia-reperfusion injury in preventing inflammation, tissue degeneration, and apoptosis in rat skeletal muscle.
    Güneysu E; Koçman AE; Özatik O; Ovali C; Can B; Alataş İÖ; Sevin MB
    Turk J Med Sci; 2017 Jun; 47(3):1028-1036. PubMed ID: 28618761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospects of prostanoid therapy. Preliminary results.
    Castagno PL; Di Molfetta L; Merlo M; Barile G; Violato F; Buzzacchino A; Ponzio F
    Minerva Cardioangiol; 2000; 48(1-2):9-18. PubMed ID: 10829583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of vasodilatory prostaglandins with respect to cAMP-mediated phosphorylation of a target substrate in intact human platelets.
    Nolte C; Eigenthaler M; Schanzenbächer P; Walter U
    Biochem Pharmacol; 1991 Jul; 42(2):253-62. PubMed ID: 1713458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of alprostadil and iloprost on renal, lung, and skeletal muscle injury following hindlimb ischemia-reperfusion injury in rats.
    Erer D; Özer A; Demirtaş H; Gönül İI; Kara H; Arpacı H; Çomu FM; Oktar GL; Arslan M; Küçük A
    Drug Des Devel Ther; 2016; 10():2651-8. PubMed ID: 27601882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between iloprost and alprostadil in the treatment of Raynaud's phenomenon.
    Marasini B; Massarotti M; Bottasso B; Coppola R; Del Papa N; Maglione W; Comina DP; Maioli C
    Scand J Rheumatol; 2004; 33(4):253-6. PubMed ID: 15370722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparative pharmacoeconomic analysis of prostanoids for peripheral arterial occlusive].
    Avksent'eva MV; Chupin AV
    Angiol Sosud Khir; 2013; 19(3):15-9. PubMed ID: 24300486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of intravenous prostaglandin E1 on arterial compliance: a randomized controlled trial.
    Mlekusch W; Schillinger M; Sabeti S; Al-Awami M; Gschwandtner M; Minar E
    Vasa; 2004 Aug; 33(3):131-6. PubMed ID: 15461064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of iloprost on pain-free walking distance and clinical outcome in patients with severe stage IIb peripheral arterial disease: the FADOI 2bPILOT Study.
    Mazzone A; Di Salvo M; Mazzuca S; Valerio A; Gussoni G; Bonizzoni E; Campanini M; Vescovo G; Nozzoli C;
    Eur J Clin Invest; 2013 Nov; 43(11):1163-70. PubMed ID: 24102344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microcirculation and tolerability following i.v. infusion of PGE1 and iloprost: a randomized cross-over study in patients with critical limb ischemia.
    Schellong S; Altmann E; von Bilderling P; Rudofsky G; Waldhausen P; Rogatti W
    Prostaglandins Leukot Essent Fatty Acids; 2004 Jun; 70(6):503-9. PubMed ID: 15120713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two randomised and placebo-controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. The Oral Iloprost in severe Leg Ischaemia Study Group.
    Eur J Vasc Endovasc Surg; 2000 Oct; 20(4):358-62. PubMed ID: 11038148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia.
    Brass EP; Anthony R; Dormandy J; Hiatt WR; Jiao J; Nakanishi A; McNamara T; Nehler M;
    J Vasc Surg; 2006 Apr; 43(4):752-9. PubMed ID: 16616232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous infusion of iloprost and prostaglandin E1 (PGE1): cardiovascular profile in anaesthetized rabbits.
    Müller B; Maass B; Stürzebecher S
    Prog Clin Biol Res; 1989; 301():401-5. PubMed ID: 2477856
    [No Abstract]   [Full Text] [Related]  

  • 16. [Prostaglandin interaction in the human liver].
    Virgolini I; Weiss K; Hermann M; Müller C; Sinzinger H
    Klin Wochenschr; 1989 Dec; 67(24):1229-35. PubMed ID: 2483738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerance development to antimitogenic actions of prostacyclin but not of prostaglandin E1 in coronary artery smooth muscle cells.
    Zucker TP; Bönisch D; Hasse A; Grosser T; Weber AA; Schrör K
    Eur J Pharmacol; 1998 Mar; 345(2):213-20. PubMed ID: 9600640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of local treatment with iloprost, a prostacyclin analogue, in patients with Peyronie's disease: a phase I study.
    Pavone C; Napoli G; Caruana G; Alonge V; Usala M; Abbadessa D
    BJU Int; 2012 Jul; 110(1):117-21. PubMed ID: 22176734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iloprost as an acute kidney injury-triggering agent in severely atherosclerotic patients.
    Uyar ME; Yucel P; Ilin S; Bal Z; Yildirim S; Uyar AS; Akay T; Tutal E; Sezer S
    Cardiovasc J Afr; 2016; 27(3):128-133. PubMed ID: 27841898
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.